Openly accessible

Potential for novel biomarkers in diabetes-associated chronic kidney disease: Epigenome, metabolome, and gut microbiome

Lecamwasam, Ashani, Ekinci, EI, Saffery, R and Dwyer, Karen 2020, Potential for novel biomarkers in diabetes-associated chronic kidney disease: Epigenome, metabolome, and gut microbiome, Biomedicines, vol. 8, no. 9, pp. 1-14, doi: 10.3390/BIOMEDICINES8090341.

Attached Files
Name Description MIMEType Size Downloads

Title Potential for novel biomarkers in diabetes-associated chronic kidney disease: Epigenome, metabolome, and gut microbiome
Author(s) Lecamwasam, Ashani
Ekinci, EI
Saffery, RORCID iD for Saffery, R orcid.org/0000-0002-4376-9720
Dwyer, Karen
Journal name Biomedicines
Volume number 8
Issue number 9
Article ID 341
Start page 1
End page 14
Total pages 14
Publisher MDPI
Place of publication Basel, Switzerland
Publication date 2020
ISSN 2227-9059
2227-9059
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Medicine, Research & Experimental
Pharmacology & Pharmacy
Research & Experimental Medicine
diabetes
chronic kidney disease
biomarker
epigenetics
metabolomics
gut microbiome
DNA METHYLATION
WIDE ASSOCIATION
REVEALS
BLOOD
QUANTIFICATION
EPIDEMIOLOGY
NEPHROPATHY
PROGRESSION
STAGE
Summary Diabetes-associated chronic kidney disease is a pandemic issue. Despite the global increase in the number of individuals with this chronic condition together with increasing morbidity and mortality, there are currently only limited therapeutic options to slow disease progression. One of the reasons for this is that the current-day “gold standard” biomarkers lack adequate sensitivity and specificity to detect early diabetic chronic kidney disease (CKD). This review focuses on the rapidly evolving areas of epigenetics, metabolomics, and the gut microbiome as potential sources of novel biomarkers in diabetes-associated CKD and discusses their relevance to clinical practice. However, it also highlights the problems associated with many studies within these three areas—namely, the lack of adequately powered longitudinal studies, and the lack of reproducibility of results which impede biomarker development and clinical validation in this complex and susceptible population.
Language eng
DOI 10.3390/BIOMEDICINES8090341
Indigenous content off
HERDC Research category C1 Refereed article in a scholarly journal
Free to Read? Yes
Persistent URL http://hdl.handle.net/10536/DRO/DU:30143200

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 77 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 16 Oct 2020, 08:13:47 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.